Expert Opinion on Therapeutic Targets

A novel IKK inhibitor suppresses heart failure and chronic remodeling after myocardial ischemia via MMP alteration
pp. 1469-1476(8)
Authors: Wakatsuki, Shin; Suzuki, Jun-ichi; Ogawa, Masahito; Masumura, Mayumi; Muto, Susumu; Shimizu, Tomoko; Takayama, Kiyoshi; Itai, Akiko; Isobe, Mitsuaki

Plasma levels of osteopontin before and 24 h after percutaneous coronary intervention
pp. 1477-1480(4)
Authors: Georgiadou, P; Iliodromitis, EK; Kolokathis, F; Mavroidis, M; Andreadou, I; Demopoulou, M; Varounis, Ch; Capetanaki, Y; Boudoulas, H; Kremastinos, D Th

Toll-like receptors as therapeutic targets in cystic fibrosis
pp. 1481-1495(15)
Authors: Greene, Catherine M; Branagan, Peter; McElvaney, Noel G

Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development
pp. 1497-1507(11)
Authors: Müller, Norbert

Autophagy: a target for therapeutic interventions in myocardial pathophysiology
pp. 1509-1522(14)
Authors: Halapas, Antonis; Armakolas, Athanasios; Koutsilieris, Michael

Current and emerging paradigms in the therapeutic management of atherosclerosis
pp. 1523-1546(24)
Author: Tiwari, Atul

Targeting cerebrovascular Rho-kinase in stroke
pp. 1547-1564(18)
Authors: Shin, Hwa Kyoung; Salomone, Salvatore; Ayata, Cenk

Targeting PPAR as a therapy to treat multiple sclerosis
pp. 1565-1575(11)
Authors: Bright, John J; Walline, Crystal C; Kanakasabai, Sarvanan; Chakraborty, Sharmistha

The role of matrix metalloproteinases in the pathophysiology and progression of human nervous system malignancies: a chance for the development of targeted therapeutic approaches?
pp. 1577-1586(10)
Authors: Koutroulis, Ioannis; Zarros, Apostolos; Theocharis, Stamatios

Targeting the angiotensin pathway in idiopathic pulmonary fibrosis
pp. 1587-1590(4)
Author: Antoniu, Sabina A

Mast cells in health and disease: from basic science to clinical application
pp. 1591-1594(4)
Authors: Kirchhoff, Dennis; Bischoff, Stephan C; Maurer, Marcus; Zollner, Thomas M